Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer

Abstract

Gastric cancer (GC) remains the fifth most common cancer worldwide. Heat-shock protein 90 (HSP90) has become an attractive therapeutic target in treating cancers, because of its abnormally high expression in cancers. Several successful cases of HSP90 inhibitors capable of inhibiting GC inspired us to try ganetespib, a clinically promising and actively investigated second-generation HSP90 inhibitor in GC treatment. In our study, we show that ganetespib markedly reduced the growth of MGC-803 and also significantly inhibited the growth of SGC-7901 and MKN-28 in a dose-dependent manner. It induced G2/M cell-cycle arrest and apoptosis in all three cell lines, together with the related markers affected significantly. Mechanistically, ganetespib caused pronounced decrease of expression of classic HSP90 client proteins. Specifically, it greatly affected epidermal growth factor receptor (EGFR) signaling cascades by markedly decreasing the levels of total EGFR and EGFR on cell membranes. EGFR knockdown also induced cell-cycle arrest and apoptosis accompanied with a decrease of several EGFR downstream proteins. These results strongly support that EGFR signaling greatly contributes to the ganetespib inhibitory effects. Besides, we found that the responses of GC cell lines to ganetespib correlated well with their EGFR expression levels: MGC-803, as well as AGS and BGC-803, with higher EGFR expression responded to ganetespib better, whereas SGC-7901 and MKN-28 with lower EGFR levels were much less sensitive to ganetespib. Although SGC-7901 and MKN-28 were not very sensitive to ganetespib, ganetespib worked synergistically with radiation and cisplatin in killing them. Importantly, ganetespib significantly inhibited the growth of xenograft tumors in vivo as a single agent or in combination with cisplatin. Results of hematoxylin/eosin staining, TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assays, and immunohistochemistry staining of phosphorylated cyclin-dependent kinase 1 (pCDK1), EGFR and Ki-67 revealed significant differences in ganetespib-treated tumors. Collectively, our data suggest that ganetespib, as a new potent treatment option, can be used for the molecularly targeted therapy of GC patients according to their expression profiles of EGFR. Cell Death and Disease (2015) 6, e1595; doi:10.1038/cddis.2014.555; published online 15 January 2015Gastric cancer (GC) remains the fifth most common cancer worldwide, with an estimated 9 52 000 new cases (7% of total cancer incidence) and 7 23 000 deaths (9% of total cancer mortality) in 2012. 1 As a highly aggressive and lethal malignancy, the aggressive nature of GC is linked to mutations in tumor suppressor genes, oncogenes, growth factors and their receptors, and so on. 2 Till now, there are few effective treatment options for advanced patients with distant metastasis or recurrence. 3 The detailed mechanisms that regulate GC are not yet fully understood; therefore, such situations underscore the persistent unmet need to identify therapeutics that target pa...

Methylene Blue Reduces Acute Cerebral Ischemic Injury via the Induction of Mitophagy

“…The sections were stained using hematoxylin and eosin (H&E) according to a previously described standard protocol (38).…”

Tissue transglutaminase-1 promotes stemness and chemoresistance in gastric cancer cells by regulating Wnt/β-catenin signaling

“…We next compared the expression levels of TGM1 in four gastric cancer cell lines (BGC823, SGC7901, MGC803 and AGS), to those in human normal GES-1 and found that TGM1 was consistently upregulated in all four gastric cancer cell lines (Figure 1(c)). BGC823 and MGC803 cells are poorly differentiated, SGC7901 cells are moderately differentiated and AGS cells were poorly to moderately differentiated, 24,25 but there were no significant differences between poorly and moderately differentiated cells. Because SGC7901 and MGC803 cells expressed relatively high levels of TGM1, they were selected for further functional analyses.…”

Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas

“…This hypothesis is further supported by recent observations that HSP90 influences the function of a number of other signaling components that are overexpressed, or otherwise deregulated in cancer, including transcription factors, E3-ligases, metabolic enzymes, and protein translational machinery (Taipale et al 2014); (Liu et al 2015); (Solier et al 2012); (Supplemental Table 2). While development of specific inhibitors of these various signaling components lags behind the development of KIs, preliminary findings provide evidence of synergy (Brady et al 2015).…”